NASDAQ:HURA TuHURA Biosciences 11/13/2023 Earnings Report $3.73 -0.17 (-4.36%) Closing price 04:00 PM EasternExtended Trading$4.01 +0.28 (+7.48%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast TuHURA Biosciences EPS ResultsActual EPS-$63.99Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ATuHURA Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATuHURA Biosciences Announcement DetailsQuarterDate11/13/2023TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsTuHURA Biosciences' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile TuHURA Biosciences Earnings HeadlinesTuHURA Biosciences, Inc. (HURA)May 6 at 3:30 PM | finance.yahoo.comInnovative Immune Therapy Approach Drives Buy Rating for TuHURA BiosciencesMay 6 at 2:43 PM | tipranks.comVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was dead… And the office was permanently closed? That's not some paranoid fantasy. It's the nightmare already unfolding across America—fueled by sweeping government cuts and a crumbling Social Security system.May 6, 2025 | Investors Alley (Ad)TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)May 5 at 8:00 AM | prnewswire.comTuHURA And Kineta Present Updated Results From Phase I-II Study Of KVA12123April 30, 2025 | nasdaq.comTuHURA Biosciences: Promising Developments in Anti-VISTA Antibody and DNA-based Immune Activator Justify Buy RatingApril 29, 2025 | tipranks.comSee More TuHURA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email. Email Address About TuHURA BiosciencesTuHURA Biosciences (NASDAQ:HURA), Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.View TuHURA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Palantir Stock Drops Despite Stellar Earnings: What's Next?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's EarningsAmazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Upcoming Earnings ARM (5/7/2025)AppLovin (5/7/2025)Fortinet (5/7/2025)MercadoLibre (5/7/2025)Cencora (5/7/2025)Carvana (5/7/2025)Walt Disney (5/7/2025)Emerson Electric (5/7/2025)Johnson Controls International (5/7/2025)Lloyds Banking Group (5/7/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
